Patients treated with ruxolitinib often experience significant symptom relief, particularly in terms of reduced spleen size and improved quality of life. Clinical trials have demonstrated that the drug can reduce spleen volume by at least 35% in a significant proportion of patients with myelofibrosis. Additionally, ruxolitinib has been shown to improve overall survival rates compared to other treatments.
